Related references
Note: Only part of the references are listed.Review: Radionuclide Molecular Imaging Targeting HER2 in Breast Cancer with a Focus on Molecular Probes into Clinical Trials and Small Peptides
Shushan Ge et al.
MOLECULES (2021)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
An Integrin Alpha 6-Targeted Radiotracer with Improved Receptor Binding Affinity and Tumor Uptake
Qi Luo et al.
BIOCONJUGATE CHEMISTRY (2020)
Imaging and monitoring HER2 expression in breast cancer during trastuzumab therapy with a peptide probe 99mTc-HYNIC-H10F
Yue Wu et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2020)
Peptide Based Imaging Agents for HER2 Imaging in Oncology
Maxwell Ducharme et al.
MOLECULAR IMAGING (2020)
First-in-Human Human Epidermal Growth Factor Receptor 2-Targeted Imaging Using Zr-89-Pertuzumab PET/CT: Dosimetry and Clinical Application in Patients with Breast Cancer
Gary A. Ulaner et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Targeting HER2 in Nuclear Medicine for Imaging and Therapy
Adriana V. F. Massicano et al.
MOLECULAR IMAGING (2018)
SPECT/CT Imaging of the Novel HER2-Targeted Peptide Probe 99mTc-HYNIC-H6F in Breast Cancer Mouse Models
Liqiang Li et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
Phase I Study of Ga-68-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma
Marleen Keyaerts et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
Tumor-Specific Binding of Radiolabeled PEGylated GIRLRG Peptide: A Novel Agent for Targeting Cancers
Vaishali Kapoor et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
Survival in patients with non-metastatic breast cancer treated with adjuvant trastuzumab in clinical practice
Christopher M. Gallagher et al.
SPRINGERPLUS (2016)
Potential of overcoming resistance to HER2-targeted therapies through the PI3K/Akt/mTOR pathway
Sharon T. Wilks
BREAST (2015)
HER2-directed therapy: current treatment options for HER2-positive breast cancer
Shahid Ahmed et al.
BREAST CANCER (2015)
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
F. Cardoso et al.
BREAST (2014)
HER2 testing: Current status and future directions
Edith A. Perez et al.
CANCER TREATMENT REVIEWS (2014)
18F-FDG uptake in breast cancer correlates with immunohistochemically defined subtypes
Hye Ryoung Koo et al.
EUROPEAN RADIOLOGY (2014)
Introduction of an 8-Aminooctanoic Acid Linker Enhances Uptake of Tc-99m-Labeled Lactam Bridge-Cyclized alpha-MSH Peptide in Melanoma
Haixun Guo et al.
JOURNAL OF NUCLEAR MEDICINE (2014)
First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the 111In-ABY-025 Affibody Molecule
Jens Sorensen et al.
JOURNAL OF NUCLEAR MEDICINE (2014)
Imaging EGFR and HER2 by PET and SPECT: A Review
Emily B. Corcoran et al.
MEDICINAL RESEARCH REVIEWS (2014)
Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab
W. J. Gradishar
ANNALS OF ONCOLOGY (2013)
Potent Retro-Inverso D-Peptide for Simultaneous Targeting of Angiogenic Blood Vasculature and Tumor Cells
Ying Li et al.
BIOCONJUGATE CHEMISTRY (2013)
HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment
D. Groheux et al.
BRITISH JOURNAL OF CANCER (2013)
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
64Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer
Kenji Tamura et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
Pilot study of 68Ga-DOTA-F(ab′)2-trastuzumab in patients with breast cancer
Volkan Beylergil et al.
NUCLEAR MEDICINE COMMUNICATIONS (2013)
Association of primary tumour FDG uptake with clinical, histopathological and molecular characteristics in breast cancer patients scheduled for neoadjuvant chemotherapy
B. B. Koolen et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2012)
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Marco Gerlinger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
HER2 Protein and Gene Variation between Primary and Metastatic Breast Cancer: Significance and Impact on Patient Care
Alessandra Fabi et al.
CLINICAL CANCER RESEARCH (2011)
Evaluation of In-111-Labeled Cyclic RGD Peptides: Effects of Peptide and Linker Multiplicity on Their Tumor Uptake, Excretion Kinetics and Metabolic Stability
Jiyun Shi et al.
THERANOSTICS (2011)
Peptide-Based Probes for Targeted Molecular Imaging
Seulki Lee et al.
BIOCHEMISTRY (2010)
Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer
E. C. Dijkers et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
The role of HER2 in cancer therapy and targeted drug delivery
Wanyi Tai et al.
JOURNAL OF CONTROLLED RELEASE (2010)
Development and Characterization of Clinical-Grade 89Zr-Trastuzumab for HER2/neu ImmunoPET Imaging
Eli C. F. Dijkers et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Improving Tumor-Targeting Capability and Pharmacokinetics of Tc-99m-Labeled Cyclic RGD Dimers with PEG(4) Linkers
Lijun Wang et al.
MOLECULAR PHARMACEUTICS (2009)
HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy
Alfredo Santinelli et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
[64Cu-NOTA-8-Aoc-BBN(7-14)NH2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues
Adam F. Prasanphanich et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Improved targeting of the αvβ3 integrin by multimerisation of RGD peptides
Ingrid Dijkgraaf et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2007)
Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer
Patrick J. Perik et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Partial D-amino acid substitution:: Improved enzymatic stability and preserved Ab recognition of a MUC2 epitope peptide
R Tugyi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Share Paper
